Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RARadiopharm Theranostics Limited logo

Radiopharm Theranostics Limited (RADX)

NASDAQ Capital Market · Currency in USD
$1.01 ▲ +0.06 (+6.32%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.00 ▼ -0.01 (-1.00%)
After hours: Oct 23, 5:07 PM ET

Summary

Previous Close
$0.95
Open
$1.07
Day's Range
$1.00 – $1.07
52 Week Range
$0.90 – $16.25
Volume
32,465
Avg. Volume
69,879
Market Cap
$1.30M
Beta (5Y Monthly)
0.80
PE Ratio (TTM)
--
EPS (TTM)
-$4.70
Earnings Date
Feb 26, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: Radiopharm Theranostics Limited

Sector
Healthcare
Industry
Biotechnology
Full-time employees
14
CEO
Riccardo Canevari

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers).

Earnings

Next report: Fri, Feb 26, 2027
EPS estimate -$1.05 · Revenue est. $699.25K
DateEst.Actual
Aug 28, 2026-$1.67-$1.20Beat
Feb 27, 2026-$1.51-$2.25Miss
Aug 29, 2025-$1.58-$1.78Miss
Feb 28, 2025-$1.49-$1.91Miss
Feb 29, 2024–-$14.10
Feb 28, 2023–-$8.71

Analyst view

Consensus price target
$6.00 ▲ +494.1%
Range $6.00 – $6.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on RADX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.